Novo Nordisk puts $1.2B on the table for Prothena’s ATTR drug, teeing up Alnylam challenge and cardiovascular expansion

Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program, which was stalled by the pandemic last year.

The deal will see Novo pay $100 million in upfront and near-term fees for worldwide rights to the phase 2-ready anti-amyloid immunotherapy PRX004.